Heart Matters-logo

Heart Matters

ReachMD

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more. So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Location:

United States

Networks:

ReachMD

Description:

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more. So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Language:

English


Episodes

Active Aging: Preventing Heart Failure in Older Women with Exercise

3/19/2024
Host: Javed Butler, MD, MBA, MPH Guest: Michael J. LaMonte, PhD, MPH The American Heart Association recommends physical activity to help lower the risk of heart failure, but how much exercise is needed, especially for older women, to lower that risk? According to a recent study, even just low-intensity exercise for 30 minutes is associated with a 25 percent lower risk of overall heart failure. Dive further into the findings with Dr. Javed Bulter and Dr. Michael LaMonte, a Research Professor of Epidemiology and Environmental Health at the University of Buffalo.

Duration:00:11:33

Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link

3/19/2024
Host: Javed Butler, MD, MBA, MPH Guest: Jeffrey Wilson, MD There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined by Dr. Jeffrey Wilson, Allergist and Immunologist in the Department of Medicine’s Division of Asthma, Allergy, and Immunology at the University of Virginia.

Duration:00:11:47

AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD

1/16/2024
Host: Javed Butler, MD, MBA, MPH Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S. For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.

Duration:00:12:24

Implementing LDL-C—Lowering Therapy: Conversations with the Care Team

12/19/2023
Guest: Michael Farbaniec, MD Guest: Emma Hegwood, DO Guest: Britt Heller, MSN, RN Explore the acquisition pathways and learn key strategies for implementing LEQVIO® (inclisiran) into your practice with Dr Michael Farbaniec, Lipid Clinic Director in Pennsylvania, Dr Emma Hegwood, a cardiology fellow with Dr Farbaniec in the Clinical World of Cardiology and also a LEQVIO patient, and Care Coordinator and Registered Nurse Brittany Heller. Dr Farbaniec, Dr Hegwood, and Ms Heller have all been compensated for their time.

Duration:00:08:36

Pharmacist-Prescribing and Hypertension Management: An Economic Benefit

12/12/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Dave L. Dixon, PharmD, FACC, FCCP, FNLA, BCPS, BCACP, CDE, CLS What would the cost-effectiveness look like if the uptake of a pharmacist-prescribing model for hypertension were to be put into practice? A new study shows that a pharmacist-prescribing method could have significant economic impact on the U.S. healthcare system. Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Dave Dixon, Nancy L. and Ronald H. McFarlane Professor of Pharmacy at Virginia Commonwealth University School of Pharmacy, to discuss the findings from the study, titled “Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States,” which was published in JAMA Network.

Duration:00:10:42

Improving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity

9/22/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Javed Butler, MD, MBA, MPH There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.

Duration:00:11:01

A Discussion on Statins to Lower CVD Risk for HIV Patients

8/13/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Steve Grinspoon, MD The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Principal Investigator and Professor of Medicine at Harvard Medical School in Boston.

Duration:00:12:00

A Discussion on the Updated Recommendations for Managing Dyslipidemia in Adults

7/6/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Biomedical Research.

Duration:00:09:15

Identifying Cardiovascular Risk Factors for HIV Patients

7/5/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Steve Grinspoon, MD Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Duration:00:11:20

Exploring Emerging Non-Statin LDL Lowering Therapies

6/28/2023
Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Maya S. Safarova, MD, PhD, FNLA Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering therapies.

Duration:00:12:36

Assessing the Effectiveness of Lp(a) Lowering Therapies in Clinical Trials

6/26/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Alan S. Brown, MD, FACC, FAHA, FNLA Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Duration:00:08:46

Letters from the Heart: People Should Know About Lp(a)

6/22/2023
It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Duration:00:04:29

Understanding Lp(a): Clinical Implications of an Underrecognized Genetic Dyslipidemia

6/22/2023
Guest: Santica Marcovina, PhD, ScD Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Duration:00:08:59

The ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein

6/22/2023
Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Duration:00:04:59

Stanford Surgeons Perform First Beating-Heart Procedure

5/30/2023
Host: Javed Butler, MD, MBA, MPH Guest: John W. MacArthur With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.

Duration:00:09:31

Treating Tricuspid Valve Regurgitation With Novel Replacement Device

5/11/2023
Host: Javed Butler, MD, MBA, MPH Guest: Pedro A Villablanca Spinetto, MD A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.

Duration:00:09:16

Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management

4/20/2023
Host: Saurabh Malhotra, MD, MPH The Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management will consist of five 2.5-hour virtual live sessions, June 2-4, 2023. The case-based sessions will provide an in-depth discussion of cardiac amyloidosis and its pathogenesis, diagnostic techniques and pitfalls, management strategies, mechanisms to facilitate early diagnosis, treatment and management, and challenging case studies presented by leading internationally recognized experts in transthyretin cardiac amyloidosis.

Duration:00:02:59

Exploring the Use of AI to Detect HFpEF

4/10/2023
Guest: Patricia A. Pellikka, M.D. Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.

Duration:00:03:28

Updates from ACC 2023: Examining Transcatheter Repair Study Data

3/29/2023
Guest: Paul Sorajja, MD TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.

Duration:00:03:00

Cardio-Oncology: Key Clinical Data from ACC.23

3/23/2023
Guest: Ana Barac, MD, PhD The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

Duration:00:03:29